Chisun Bio

Chisun Bio is a clinical-stage biotechnology company based in South Korea that focuses on developing innovative small molecule therapeutics for metabolic disorders. The company's core expertise lies in the discovery of highly selective Thyroid Hormone Receptor beta (THR-beta) agonists designed to treat Metabolic Dysfunction-Associated Steatohepatitis (MASH) and dyslipidemia. Their lead candidate, CSB-001, is engineered for liver-specific action to avoid the cardiotoxicity and bone density issues associated with alpha-receptor activation. By utilizing a proprietary structural biology platform, Chisun Bio aims to provide safer and more effective treatment options for the growing global population affected by metabolic syndrome. The company is currently advancing its pipeline through early-stage clinical trials with a focus on global commercialization.